2.2.10. VISCOSITY - ROTATING VISCOMETER METHOD
EUROPEAN PHARMACOPOEIA 7.0 2.2.10. Viscosity - Rotating viscometer method Figure 2.2.10.-2 CONE-PLATE VISCOMETERS (ABSOLUTE VISCOMETERS) In the cone-plate viscometer, the liquid is introduced into the gap between a flat disc and a cone forming a define angle. Viscosity measurement can be performed by rotating the cone
Download 2.2.10. VISCOSITY - ROTATING VISCOMETER METHOD
Information
Domain:
Source:
Link to this page:
Documents from same domain
<1117> MICROBIOLOGICAL BEST LABORATORY …
www.drugfuture.com708 〈1117〉 Microbiological Best Laboratory Practices / General Information USP 35 glassware or from prior materials used in the glassware. Be Media should be labeled properly with batch or lot num-
<1227> VALIDATION OF MICROBIAL RECOVERY …
www.drugfuture.comUSP 35 General Information / 〈1227〉 Validation of Microbial Recovery 883 〈1227〉 VALIDATION OF culture preparation. The conditions of organism preparation and storage must be standardized for the neutralizer evalua-MICROBIAL RECOVERY FROM tion and should reflect the conditions of the antimicrobial
2.2.32. LOSS ON DRYING - 药物在线-快捷药物信息 …
www.drugfuture.com2.2.33. Nuclear magnetic resonance spectrometry EUROPEAN PHARMACOPOEIA 7.0 01/2009:20233 2.2.33. NUCLEAR MAGNETIC RESONANCE SPECTROMETRY INTRODUCTION Nuclearmagneticresonance(NMR)spectrometryisananalytical
2.2.46. CHROMATOGRAPHIC SEPARATION …
www.drugfuture.com2.2.45. Supercritical fluid chromatography EUROPEAN PHARMACOPOEIA 7.0 Control solutions.In addition to the TOC water control, prepare suitable blank solutions or other solutions needed for establishing the baseline or for calibration adjustments
2.6.12. MICROBIOLOGICAL - DrugFuture
www.drugfuture.com2.6.12. Microbial enumeration tests EUROPEAN PHARMACOPOEIA 7.0 Table 2.6.12.-1. – Preparation and use of test micro-organisms Growth …
2.4. LIMIT TESTS - DrugFuture
www.drugfuture.comEUROPEAN PHARMACOPOEIA 7.0 2.4.4. Chlorides 2.4. LIMIT TESTS 01/2008:20401 2.4.1. AMMONIUM Unlessotherwiseprescribed,usemethodA. METHOD A ...
2.2. PHYSICAL AND PHYSICOCHEMICAL METHODS
www.drugfuture.com2.2.2. Degree of coloration of liquids EUROPEAN PHARMACOPOEIA 7.0 dilute suspensions containing small particles. Linearity between turbidity and concentration must be established by constructing
EUROPEAN PHARMACOPOEIA 7 - DrugFuture
www.drugfuture.com2.2.25. Absorption spectrophotometry, ultraviolet and visible EUROPEAN PHARMACOPOEIA 7.0 acquired using suitable purged instruments or ensuring that sample and background single beam spectra are acquired under
5.1.3. EFFICACY OF ANTIMICROBIAL PRESERVATION
www.drugfuture.comEUROPEAN PHARMACOPOEIA 7.0 5.1.3. Efficacy of antimicrobial preservation suspensions may be presented in sealed ampoules. Biological indicators are prepared in such a way that they can be stored
<1151> PHARMACEUTICAL DOSAGE FORMS - …
www.drugfuture.com766 〈1151〉 Pharmaceutical Dosage Forms / General Information USP 35 Figure 1. Compendial Taxonomy for Pharmaceutical Dosage Forms. volumes recommended in the accompanying table are usu- Identification—Identification tests are discussed in the
Related documents
EUROPEAN PHARMACOPOEIA 5 - uspbpep.com
uspbpep.comEUROPEAN PHARMACOPOEIA 5.0 2.9.2. Disintegration of suppositories and pessaries to a mechanical device capable of raising and lowering it smoothly at constant frequency between 29 and 32 cycles per minute, through a distance of 55 ± 2 mm. The assembly is suspended in the specified liquid medium in a suitable vessel, preferably a 1 litre beaker.
The United States Pharmacopeia - WHO
www.who.int• National pharmacopoeia(s) No • Regional pharmacopoeia(s) No • International pharmacopoeia(s) No Note: FDA MAPP 5310.7 notes the use of the British, Japanese, and European Pharmacopoeias during CMC review for INDs and NDAs. The MAPP states, however, that these compendia are not intended to be in place of or
The European Pharmacopoeia and Your Logo certificates of ...
www.ema.europa.eu7 The European Pharmacopoeia and certificates of suitability (CEP) What must comply? • Mandatory for all substances for pharmaceutical use • Ingredients (incl. excipients) of final formulation • Components of solvents, buffers etc. in or used to make up final formulation
5.1.3. EFFICACY OF ANTIMICROBIAL PRESERVATION
www.drugfuture.comEUROPEAN PHARMACOPOEIA 7.0 5.1.3. Efficacy of antimicrobial preservation suspensions may be presented in sealed ampoules. Biological indicators are prepared in such a way that they can be stored under defined conditions; an expiry date is set. Micro-organisms of the same bacterial species as the bacteria
Guideline Summary Requirements - European Medicines …
www.ema.europa.eu2.1 Certificate of Suitability to the Monograph of the European Pharmacopoeia (CEP) The active substance manufacturer should submit documentation to the European Pharmacopoeia Secretariat with a view to evaluating the suitability of the pharmacopoeial monograph in relation to the manufacturing method actually used, cf. Appendix I of the
INDEX OF PHARMACOPOEIAS - WHO
www.who.intCzech Republic 1. Czech Pharmacopoeia Commission Ministry of Health State Institute for Drug Control Šrobárova 48, 100-41 Prague 10, Czech Republic The Czech Pharmacopoeia Pharmacopoea Bohemica MMV 2. Vydala Grada Publishing a.s. Volumes 1-3 2005 Czech U Pruhonu 466/22, Praha 7-Holešovice,